- "The continued removal of litigation overhangs is a positive," Baird notes, referencing Accretive Health's (AH +1.8%) settlement of an FTC investigation tied to the security of patient information.
- The company has also learned the regulator won't pursue enforcement action related to AH's ER debt collection activities.
- Nevertheless, analyst Eric Coldwell is staying on the sidelines with a Neutral rating.
- Although "sentiment is due for gradual improvement ... we see no need to rush in," Baird says, adding that "there are a lack of catalysts between here and March."
- Price target is $10.
Baird stays Neutral on Accretive Health despite removal of regulatory risk
Dec 31 2013, 15:27 ET